Gustave Roussy, Cancer Campus, Grand Paris

This early-phase trial tested whether adding the immunotherapy drug durvalumab to standard chemotherapy is safe for people with advanced head and neck cancer. The study enrolled 14 adults with untreated, non-spread cancer. The goal was to find the best dose and check for side eff…

This study tested whether the drug olaparib could help control advanced non-small cell lung cancer (NSCLC) after initial chemotherapy. Only patients whose cancer responded to platinum-based chemotherapy were eligible. The trial was terminated early, and results are not yet fully …

This study tested a combination of two drugs (rucaparib and atezolizumab) in 130 adults with advanced solid tumors that had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combo could shrink tumors. The trial was terminated early, so resu…

This study tested a combination of two drugs, niraparib and dostarlimab, in adults with advanced solid tumors that had DNA repair problems or were sensitive to platinum chemotherapy. The goal was to see how many patients' tumors shrank or disappeared. The trial was stopped early …

This study looked at two stronger treatment plans for children with a very high-risk type of nerve cancer called neuroblastoma that did not shrink enough after standard chemotherapy. The goal was to see if these more intense treatments could help children live longer without the …

This study looked at whether giving a short course of immunotherapy (atezolizumab, alone or with other drugs) before standard treatment could boost the immune system's attack on early-stage breast cancer. It involved 33 people with triple-negative or HER2-positive breast cancer. …

This study tested a new way of combining PET and MRI scans to see how well they can map differences within lung cancer tumors. Researchers wanted to know if different doctors reading the scans would get the same results. The study included 11 adults with advanced non-small cell l…